Dizal Reports Pooled Analysis from the Trials of Sunvozertinib to Treat Non-Small Cell Lung Cancer
Shots:
- Dizal has published a pooled analysis in ESMO Lung Cancer showing sunvozertinib's promising antitumor activity and safety in EGFR TKI-resistant NSCLC, supporting further research
- The analysis combined data from three P-I and P-II trials (WU-KONG1, WU-KONG2, WU-KONG15) involving 40 NSCLC patients with EGFR mutations resistant to EGFR TKIs (with 90% patients 3L+), were treated with sunvozertinib (50–400 mg, QD)
- As of Sep 2023, sunvozertinib showed ORR of 27.5%, DCR of 60%, mDoR of 6.5mos., and mPFS of 6mos. in EGFR TKI-resistant NSCLC while patients with EGFR sensitizing and T790M mutations, ORR was 55.6%. The drug was well-tolerated with a consistent safety profile
Ref: Dizal | Image: Dizal
Related News:- Dizal Reports the Regulatory Submission of Sunvozertinib to the US FDA for Treating R/R Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
